This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lyden, P. D. Articles by Hedges, B. Search for Related Content PubMed PubMed Citation Articles by Lyden, P. D. Articles by Hedges, B.

Stroke, Vol 23, 1463-1469, Copyright © 1992 by American Heart Association

ARTICLES

Protective effect of synaptic inhibition during cerebral ischemia in rats and rabbits

PD Lyden and B Hedges
Department of Neurosciences, University of California, San Diego.

BACKGROUND: Excitatory neurotransmitters appear to cause cell death during ischemia by inducing depolarization, influx of ions, and metabolic failure in the postsynaptic neuron. If this hypothesis is correct, then postsynaptic membrane hyperpolarization and inhibition of metabolism may be protective. Antagonists of the excitotoxic amino acid glutamate protect neurons in culture and in animal models of stroke but appear to cause unacceptable side effects in humans. We propose an alternative strategy of protection using agonists of the inhibitory neurotransmitter gamma-aminobutyric acid. METHODS: We caused multifocal cerebral ischemia in rats and rabbits by injecting microspheres into the carotid circulation. We administered saline, muscimol, or MK-801 within 5 minutes of stroke onset. We used a bioassay to measure outcome. In rats, we also used learning to assess cortical function, and we performed detailed quantitative brain morphometry 3 months after infarction. RESULTS: Using the bioassay, we found that muscimol exerted a protective effect in rats (p less than 0.01). There was a dose- response effect seen in muscimol-treated rabbits. Rats treated with muscimol or MK-801 exhibited significantly better visual-spatial learning compared with saline-treated subjects (p less than 0.001). Hemisphere volume after ischemia was comparable in all groups. CONCLUSIONS: Agonists of gamma-aminobutyric acid and antagonists of glutamate appear to protect brain during ischemia. Since agonists of gamma-aminobutyric acid are known to have fewer side effects in humans, they may prove more useful in the clinical setting as neuroprotective agents.

This article has been cited by other articles:

				K. Madden, W. Clark, and N. Lessov Failure of Ischemic Neuroprotection by Potentiators of Gamma-aminobutyric Acid Clin. Med. Res., April 1, 2003; 1(2): 119 - 124. [Abstract] [Full Text] [PDF]

				P. Lyden, C. Shin, C. Jackson-Friedman, S. Hassid, A. Chong, and R. L. Macdonald Effect of Ganaxolone in a Rodent Model of Cerebral Hematoma Editorial Comment Stroke, January 1, 2000; 31(1): 169 - 175. [Abstract] [Full Text] [PDF]

				M. Shimizu-Sasamata, P. Bosque-Hamilton, P. L. Huang, M. A. Moskowitz, and E. H. Lo Attenuated Neurotransmitter Release and Spreading Depression-Like Depolarizations after Focal Ischemia in Mutant Mice with Disrupted Type I Nitric Oxide Synthase Gene J. Neurosci., November 15, 1998; 18(22): 9564 - 9571. [Abstract] [Full Text] [PDF]

				A. B. Al-Mehdi, G. Zhao, and A. B. Fisher ATP-independent Membrane Depolarization with Ischemia in the Oxygen-ventilated Isolated Rat Lung Am. J. Respir. Cell Mol. Biol., May 1, 1998; 18(5): 653 - 661. [Abstract] [Full Text]

				P. D. Lyden, C. Jackson-Friedman, L. Lonzo-Doktor, and J. P. Muizelaar Medical Therapy for Intracerebral Hematoma With the {gamma}-Aminobutyric Acid-A Agonist Muscimol Stroke, February 1, 1997; 28(2): 387 - 391. [Abstract] [Full Text]

				Z. B. Yao, X. Li, Z. C. Xu, and J. T. Povlishock GABAergic and Asymmetrical Synapses on Somata of GABAergic Neurons in CA1 and CA3 Regions of Rat Hippocampus: A Quantitative Electron Microscopic Analysis Stroke, August 1, 1996; 27(8): 1411 - 1416. [Abstract] [Full Text]

				M. D. Ginsberg Review : Neuroprotection in Brain Ischemia: An Update (Part II Neuroscientist, May 1, 1995; 1(3): 164 - 175. [Abstract] [PDF]